Ayşe Uyanık1, Yusuf Bahap1, Alpcan Ateş1, Elif Özge Doğan1, Oytun Erbaş2

1İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, İstanbul, Türkiye
2İstanbul Bilim Üniversitesi Tıp Fakültesi, Fizyoloji Anabilim Dalı, İstanbul, Türkiye

Keywords: Alternating electric fields; newly diagnosed glioblastoma; NovoTTF-100A; oncology; optune; recurrent glioblastoma; tumor treating fields.


Various pilot trials, clinical trials, and recurrent glioblastoma multiforme (GBM) in 2011 have shown that FDA-approved treatment of tumor treatment sites for use in newly diagnosed GBM treatment in 2015 may be effective in GBM treatment. Current evidence supports the use of effective antimitotic and minimally toxic effects of tumor treatment sites in GBM treatment. More studies are needed to further optimize patient selection, to determine cost-effectiveness, and to assess the effects on quality of life.